Literature DB >> 22140265

Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy--a case-control study of the outcome in children.

Giovanni Nigro1, Stuart P Adler, Giustino Parruti, Maurizio M Anceschi, Eleonora Coclite, Ilaria Pezone, Gian Carlo Di Renzo.   

Abstract

BACKGROUND: Primary cytomegalovirus (CMV) infection early in gestation causes severe disease.
METHODS: Case patients were 32 congenitally infected children aged 1-5 years who had either hearing deficit and/or psychomotor retardation and whose mothers had a confirmed or probable primary CMV infection at ≤ 20 weeks' gestation. Control subjects were 32 congenitally infected normal children whose mothers had a confirmed primary infection at ≤ 20 weeks' gestation. Case patients and control subjects were matched by the weeks of maternal gestation (± 1 week) at the mother's infection and by the child's age (± 1 year) at evaluation.
RESULTS: For the case patients and control subjects, the mean age was 3.0 years. The mean number of weeks of gestation at maternal infection was 11 weeks. The only risk factor for an affected child was the mother not receiving immunoglobulin (P = .001). Of the 32 case patients, only 4 mothers received CMV immunoglobulin, compared with 27 of the 32 mothers of control infants (adjusted odds ratio, 14 [95% confidence interval, 1.7-110]). The rate of both psychomotor retardation and hearing deficit decreased with immunoglobulin.
CONCLUSIONS: These results support the efficacy of immunoglobulins for decreasing the severity of disabilities caused by fetal CMV infection after a primary maternal infection during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22140265     DOI: 10.1093/infdis/jir718

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection.

Authors:  Lenore Pereira; Matthew Petitt; Alex Fong; Mitsuru Tsuge; Takako Tabata; June Fang-Hoover; Ekaterina Maidji; Martin Zydek; Yan Zhou; Naoki Inoue; Sanam Loghavi; Samuel Pepkowitz; Lawrence M Kauvar; Dotun Ogunyemi
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

Review 2.  CD8+ effector T cells at the fetal-maternal interface, balancing fetal tolerance and antiviral immunity.

Authors:  Tamara Tilburgs; Jack L Strominger
Journal:  Am J Reprod Immunol       Date:  2013-02-23       Impact factor: 3.886

3.  Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.

Authors:  Xiaohong Cui; Daniel C Freed; Dai Wang; Ping Qiu; Fengsheng Li; Tong-Ming Fu; Lawrence M Kauvar; Michael A McVoy
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

Review 4.  Primary Human Cytomegalovirus (HCMV) Infection in Pregnancy.

Authors:  Horst Buxmann; Klaus Hamprecht; Matthias Meyer-Wittkopf; Klaus Friese
Journal:  Dtsch Arztebl Int       Date:  2017-01-27       Impact factor: 5.594

5.  Human cytomegalovirus infection interferes with the maintenance and differentiation of trophoblast progenitor cells of the human placenta.

Authors:  Takako Tabata; Matthew Petitt; Martin Zydek; June Fang-Hoover; Nicholas Larocque; Mitsuru Tsuge; Matthew Gormley; Lawrence M Kauvar; Lenore Pereira
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

Review 6.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

Review 7.  Immunobiology of congenital cytomegalovirus infection of the central nervous system—the murine cytomegalovirus model.

Authors:  Irena Slavuljica; Daria Kveštak; Peter Csaba Huszthy; Kate Kosmac; William J Britt; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2014-07-21       Impact factor: 11.530

8.  Characterization of a discontinuous neutralizing epitope on glycoprotein B of human cytomegalovirus.

Authors:  Nadja Spindler; Pia Rücker; Sonja Pötzsch; Uschi Diestel; Heinrich Sticht; Luis Martin-Parras; Thomas H Winkler; Michael Mach
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

Review 9.  Infections and Brain Development.

Authors:  Christina N Cordeiro; Michael Tsimis; Irina Burd
Journal:  Obstet Gynecol Surv       Date:  2015-10       Impact factor: 2.347

10.  Preliminary evaluation of the safety and efficacy of standard intravenous immunoglobulins in pregnant women with primary cytomegalovirus infection.

Authors:  Ennio Polilli; Giustino Parruti; Francesca D'Arcangelo; Elisa Tracanna; Luigi Clerico; Vincenzo Savini; Francesco D'Antonio; Maurizio Rosati; Lamberto Manzoli; Domenico D'Antonio; Giovanni Nigro
Journal:  Clin Vaccine Immunol       Date:  2012-10-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.